Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia

Main Article Content

Giovanni D'Arena
Sonya De Lorenzo
Maria Luigia Vigliotti
Idanna Innocenti
Michele Cimminiello
Vittorio Simeon
Francesco Autore
Giuliana Farina
Vincenzo Patella
Vincenzo De Feo
Pellegrino Musto
Luca Laurenti

Keywords

rituximab, chronic lymphocytic leukemia, infusional adverse events

Abstract

A great advance in the treatment of all CD20 positive B-cell lymphoproliferative disorders has been achieved by the addition of anti-CD20 monoclonal antibody Rituximab to standard chemotherapy. As a consequence, Rituximab has also greatly expanded the treatment options for patients with chronic lymphocytic leukemia (CLL), a “mature” B-cell malignancy characterized by an increase in marrow and circulating neoplastic B-lymphocytes. Interestingly, several autoimmune disorders are also successfully treated with Rituximab.

[...]

Abstract 133 | PDF Downloads 57